Fundraising Fox
Brace Pharma
Venture capitalAtlanta · Late Stage · 3 people tracked
Find your way into Brace Pharma
Sign up to see every warm intro you have to Brace Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Brace Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Brace Pharma Capital invests in biopharmaceutical companies developing innovative and life-changing therapies for diseases that have a high degree of unmet medical need and insufficient treatment options. The firm invites candidate investment companies to reach out for consideration.
Source: firm website, verified Oct 2, 2026.
Team · 3 people
from the firm's websiteWhat they invest in
from 12 of 14 portfolio companiesBiotech ×11Healthtech ×6Medical Devices ×4Deep Tech ×2Consumer ×1Digital Health ×1FemTech ×1Media & Entertainment ×1
HQs:United States×9
Investments · 14 tracked
founders shown can be your intro pathBy year:2021 · 12016 · 12 dated
miRagen Therapeutics is a biopharmaceutical company developing monoclonal antibodies and other engineered protein therapeutics targeting specific receptors (IGF-1R, FcRn, and TSHR) for autoimmune and rare diseases including thyroid eye disease, Graves' disease, and various autoimmune conditions.
BiotechBoulder, US
William S. Marshall(Executive Officer, Director)Jason A. Leverone(Executive Officer)inDavid Rodman(Executive Officer)Stephen Mahoney(President, Chief Executive Officer and Director)Thomas Beetham(Chief Operating Officer)inRadhika Tripuraneni(Chief Medical Officer)in
Co-investorsBroadview VenturesMC Healthcare VenturesRidgeback CapitalAtlas VentureBoulder VenturesHeartland+1 more
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)inDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)inMichael Amoroso(President, Chief Executive Officer)in
BoardROBERT ADELMAN(Director)
Co-investorsage1Agent CapitalAliment CapitalF-Prime CapitalOCV PartnersOUP (Osage University Partners)+6 more
Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D.
BiotechHealthtechVancouver, US
ALI TEHRANI(Executive Officer, Director)inGORDON NG(Executive Officer)NEIL KLOMPAS(Executive Officer)inSURJIT DIXIT(Executive Officer)inDAVID TUCKER(Executive Officer)Paul Moore(Chief Scientific Officer)in
Co-investorsCTI Life Sciences Fund L.P.HBM Healthcare InvestmentsLumira VenturesNextech InvestWUTIF CapitalAmplitude Venture Capital
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Karl Y. Hostetler(Executive Officer, Director)inGail Maderis(Director)inKristine Ball(President & CEO)inElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRaju Gadiraju(Executive Officer)in
Co-investorsAdjuvant CapitalAvestria VenturesCanaan PartnersGaingelsGV (Google Ventures)HBM Healthcare Investments+6 more
__Twitter.png)
Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases.
BiotechDeep TechHealthtechMedical DevicesLa Jolla, US
Troy Wilson PhD., JD(Executive Officer, Director)P. Kent Hawryluk(Executive Officer)inMark E. Davis(Director)Troy Wilson(Executive Officer, Director)in
BoardTodd Brady(Director)Michael Martin PhD.(Director)
Co-investorsAvoro Capital AdvisorsF-Prime CapitalFrazier Life SciencesMoore Venture Partners
F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAdvent Life SciencesAisling CapitalAMR Action FundAstellas Venture Management LLCSofinnova PartnersSunstone Capital+4 more
Baltimore-based immunology company focused on treatments for cancer and autoimmune disorders; raised an $11.5 million Series C led by First In Ventures.
BiotechBaltimore, US
David S. Block(Executive Officer, Director)Elizabeth C. Block(Executive Officer)Raymond Shinazi(Director)Joseph Klein(Director)Mark Lerner(Director)
BoardCharles Polsky(Director)
Co-investorsFirst In Ventures
BiotechCambridge, US
Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)in
BoardJean-Francois Formela(Director)inAlan Crane(Director)inMarian Nakada(Director)inBrian Gallagher(Director)in
Co-investorsage1Sanofi VenturesAtlas VenturePolaris PartnersSR One Capital Management
Reviral operates an affiliate review site that ranks and reviews online casinos not registered with the UK's GamStop self-exclusion scheme, comparing licences, bonuses, wagering terms, payout speeds, and payment methods.
ConsumerMedia & Entertainment
Co-investorsAndera PartnersNew Leaf Venture PartnersOrbiMedWellcome Trust
BiotechNew York, US
Michael Burgess(Executive Officer)Jose Manuel Otero(Executive Officer)Robert Gould(Director)inJane Henderson(Executive Officer)inStefan Larson(Director)Patrick Machado(Director)
Co-investorsF-Prime CapitalFACIT (Fight Against Cancer Innovation Trust)Foothill VenturesVenture OntarioOrbiMedPoint72+1 more
VERO Biotech develops next-generation inhaled nitric oxide (iNO) delivery systems for patients with cardiopulmonary conditions in acute care hospital settings.
BiotechHealthtechMedical Devices
Co-investorsRunway Growth CapitalMVM Life Science Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AvrobioGeNO LLCTyrogenex
Exits · 3
3 IPOsmiRagen TherapeuticsNASDAQ: VRDNPrecision BioSciencesNASDAQ: DTILZymeworksNASDAQ: ZYME
Portfolio news
latest coverage across their companies
Frequently asked questions
- How many investments has Brace Pharma made?
- Brace Pharma has 14 tracked investments, 3 of which have exited.
- What stage does Brace Pharma invest at?
- Brace Pharma invests at the Late Stage stage.
- What sectors does Brace Pharma focus on?
- Brace Pharma focuses on Biotech, Healthtech, Medical Devices.
- Where is Brace Pharma located?
- Brace Pharma is headquartered in Atlanta, US.
- Who does Brace Pharma co-invest with?
- Brace Pharma most often shares deals with F-Prime Capital, age1, Aisling Capital, among 43 tracked co-investors.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Kreos Capital is a growth debt provider financing high-growth technology and healthcare companies across Europe and Israel. Founded in 1998, it was acquired by BlackRock in August 2023 and now operates within BlackRock's Private Markets platform.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.